PACB divested its short-read DNA sequencing technology to Illumina for $50M while experiencing massive stockholders' equity decline of 98.9% despite revenue growth.
The asset sale to Illumina represents a strategic pivot away from short-read sequencing to focus exclusively on HiFi long-read technology, but the $50M proceeds are minimal compared to the catastrophic equity erosion. The near-complete destruction of stockholders' equity from $506.6M to $5.3M signals severe dilution or massive losses that dwarf operational improvements, creating substantial risk for existing shareholders.
While revenue surged 297% to $93.5M and operating cash flow improved significantly, these positive developments are overshadowed by devastating balance sheet deterioration including 98.9% stockholders' equity decline and 37.8% asset reduction. Net losses widened dramatically to -$546.4M despite reduced R&D spending, indicating the company faced severe financial distress requiring likely massive dilution or write-downs. The financial profile suggests a company undergoing major restructuring with existing equity holders bearing enormous dilution despite operational progress.
Strong top-line growth of 297% — accelerating demand or successful expansion into new markets.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Net income declined 76.3% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 56.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow surged 46% — exceptional cash generation, highest quality earnings signal.
Total assets contracted 37.8% — asset sales, write-downs, or balance sheet optimization underway.
Receivables grew 28.8% — monitor days sales outstanding for collection efficiency.
R&D spending cut 27.9% — could signal cost discipline or concerning reduction in innovation investment.
Current assets declined 24.3% — monitor working capital adequacy and short-term liquidity.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →